NASDAQ:CLRB - Cellectar Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.8550 +0.01 (+1.18 %)
(As of 06/19/2018 04:00 PM ET)
Previous Close$0.8550
Today's Range$0.8506 - $0.9258
52-Week Range$0.84 - $2.06
Volume317,179 shs
Average Volume570,718 shs
Market Capitalization$16.82 million
P/E Ratio-0.80
Dividend YieldN/A
Beta0.69
Cellectar Biosciences logoCellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company offers CLR 131, a PDC cytotoxic radioisotope product candidate, which is in Phase I clinical study for the treatment of relapse or refractory multiple myeloma, as well as in Phase II clinical study for the treatment of B-cell malignancies; and CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease. It also provides CLR 124, a cancer-targeting positron emission tomography imaging PDC for the selective detection of tumors and metastases in a range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. In addition, the company is developing CLR 1601-PTX, CLR 1602-PTX, and CLR 1603-PTX product candidates, which are in pre-clinical research for the treatment of chemotherapy. It has strategic collaboration with Onconova Therapeutics, Inc. to develop phospholipid drug conjugates. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.

Receive CLRB News and Ratings via Email

Sign-up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLRB
CUSIPN/A
Phone608-441-8120

Debt

Debt-to-Equity RatioN/A
Current Ratio3.64
Quick Ratio3.64

Price-To-Earnings

Trailing P/E Ratio-0.80
Forward P/E Ratio-1.17
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.62 per share
Price / Book1.38

Profitability

EPS (Most Recent Fiscal Year)($1.07)
Net Income$-13,560,000.00
Net MarginsN/A
Return on Equity-178.37%
Return on Assets-139.16%

Miscellaneous

Employees15
Outstanding Shares17,710,000

Cellectar Biosciences (NASDAQ:CLRB) Frequently Asked Questions

What is Cellectar Biosciences' stock symbol?

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences Inc (NASDAQ:CLRB) issued its quarterly earnings data on Friday, May, 11th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.01. View Cellectar Biosciences' Earnings History.

When is Cellectar Biosciences' next earnings date?

Cellectar Biosciences is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Cellectar Biosciences.

Who are some of Cellectar Biosciences' key competitors?

Who are Cellectar Biosciences' key executives?

Cellectar Biosciences' management team includes the folowing people:
  • Mr. James V. Caruso, CEO, Pres & Director (Age 59)
  • Mr. Jarrod Longcor, Chief Bus. Officer (Age 45)
  • Mr. Brian M. Posner, CFO & VP (Age 56)
  • Dr. John E Friend II, M.D., Chief Medical Officer and VP (Age 48)
  • Gregory J. Lynch, Sec.

Has Cellectar Biosciences been receiving favorable news coverage?

Media coverage about CLRB stock has been trending somewhat positive on Tuesday, Accern reports. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cellectar Biosciences earned a coverage optimism score of 0.13 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 47.78 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Cellectar Biosciences?

Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellectar Biosciences' stock price today?

One share of CLRB stock can currently be purchased for approximately $0.8550.

How big of a company is Cellectar Biosciences?

Cellectar Biosciences has a market capitalization of $16.82 million. The biopharmaceutical company earns $-13,560,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Cellectar Biosciences employs 15 workers across the globe.

How can I contact Cellectar Biosciences?

Cellectar Biosciences' mailing address is 3301 AGRICULTURE DRIVE, MADISON WI, 53716. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]


MarketBeat Community Rating for Cellectar Biosciences (CLRB)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  171
MarketBeat's community ratings are surveys of what our community members think about Cellectar Biosciences and other stocks. Vote "Outperform" if you believe CLRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.